UK Markets closed

Denali Therapeutics Inc. (DNLI)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
42.59-1.92 (-4.31%)
At close: 04:00PM EST
42.59 0.00 (0.00%)
After hours: 06:03PM EST
Sign in to post a message.
  • S
    Sandra
    DNLI green on strong volume during a red day for markets... something brewing?
  • P
    Peter
    The ALS Doctors have a moral dilemma...the trials are supposed to last 18 months but by giving a placebo when they know other patients are benefiting from DNL 343, i.e. they can still swallow the oral medication, is detrimental to the health of the patient.
    Life span with ALS can be as low as 20 months and do you really want your patients to die by giving them a placebo?
  • P
    Peter
    The good (great) news is that all trials are continuing.
    No fatalities, no detrimental effects.
    2 Very good trials may be highlighted soon: anyone visiting Holland for tulip bulbs can check up on ALS since the trials are entering the extended doses...you do not extend if it doesn't work or your patient can no longer swallow!
    And finally Hunters, lets hope for the best for the children and parents.
    Thank You researchers!
  • Y
    Yahoo Finance Insights
    Denali Therapeutics reached a 52 Week low at 41.22
  • Y
    Yahoo Finance Insights
    Denali Therapeutics reached a 52 Week low at 41.22
  • Y
    Yahoo Finance Insights
    Denali Therapeutics reached a 52 Week low at 43.20
  • Y
    Yahoo Finance Insights
    Denali Therapeutics reached a 52 Week low at 42.54
  • P
    Peter
    ALS study with DNL343 is over the initial 28 day period which began on 8/11/21.
    Since there has been no mention of it failing or any toxic results, then the study with active participants is continuing.
    Although this study is supposed to take a year and a half, due to the extremely deadly disease progression, any positive news would show within a very short time, maybe within in a month of initial dosing.
    Hold on for the initial results!
    The results may already be apparent.
  • P
    Peter
    What people should know about ALS is that the life expectancy is only 2 to 5 years, so a clinical study with positive results will be apparent before the termination of this study.
    As such, positive news will result in an almost 100% chance of medical acceptance and the reversible effects of DNL343 on the neurons will be quickly established and it will be available to patients immediately.
  • F
    Farid
    What's going on with the price?
  • P
    Peter
    ""Fast Track! Lou Gehrig has swung for the fences and the "Iron Man" is trotting around the bases!
  • P
    Peter
    NL343 is taken orally...no hospital or clinic infusion.
    The average cost to treat an ALS patient is the hundreds of thousands, a pill is much less.
    2 days to find out whether Lou Gehrig is swinging for the fences!
  • P
    Peter
    Biogen throws a big party, invites all the analysts, and Denali gets the gold ring. Got to love it!
  • P
    Peter
    Understanding the recent announcement from Denali...everything is working fine. Receiving payments from various companies for studies being done and all old products and new products are advancing.
    On Hunter's disease they have gone from 5 patients to 12 and the BBB drugs are working well.
    This board is more worried about finances: Remember they have about $1.4 Billion in cash and are receiving payments for studies in the present quarter. That is almost $ 13. per share in cash.
    They will probably show a profit of $ 400 Million for the year and thus about $ 4. per share or 17 times earnings.
    The future is probably not $ 100. per share, try a multiple of $ 1,000.
    Wait for more information on January 12th!
  • D
    DF
    Can we talk about the J-Off who sells/shorts 2 shares every morning in pre-market session down 1-2%. Now he/she is playing the same game in after-hours…who does he/she think they are fooling?????
  • S
    Sandra
    Rapid response was observed in most patients (n=12) by Week 7, which is consistent with the crossing of the blood-brain barrier (BBB) and activity in tissues of the CNS.

    Furthermore, the observed decline in urine and serum heparan sulfate was consistent with improved peripheral activity with DNL310.

    Exploratory clinical data suggest improved clinical symptoms and function for all five patients enrolled in Cohort A.

    Data showed clinical improvement in overall MPS II symptoms, cognitive abilities, behavior, and physical abilities.

    The safety profile of DNL310 remained consistent with the standard of care enzyme replacement therapy.

    DNL310 was generally well tolerated, with the most common treatment-emergent adverse events being infusion-related reactions.

    Infusion reactions occurred in 12 of 17 (71%) patients, and the majority had mild or moderate reactions.

    Denali is accelerating efforts to initiate a pivotal Phase 2/3 study in 1H 2022.
  • S
    Scott
    News like today's fast track designation for Hunter Syndrome only furthers my conviction in DNLI. I love the fact Denali is still fairly under the radar and doesn't trade on the whims of most day traders. I own all my shares (decent sized position) in the mid-high teens and as strange as it sounds, am considering adding a bit to my position up here in the low-$60's. I've long said Denali is this generations Genentech and will one day reach a $100B+ valuation and possibly significantly higher. Good luck DNLI longs!
  • P
    Peter
    Nice Run! I do notice that these new highs are on low volume...absence of sellers rather than an absence of buyers. I'm glad that shareholders are taking a long term approach to allow the company to do their important research and development of their pipeline without the hype of Wall Street day traders!
  • S
    Scott
    DNLI continually making new all-time highs and yet, still an under the radar stock. The potential for this company is immense. Roche v2.0!
  • P
    Peter
    Exciting news about Hunter's...3 months of results to be discussed. Only a small amount of patients have Hunter's, around 500, in the USA, but the BBB transport system can be applied to other neurodegenerative diseases.
    Thanks for the great work!